After SunTrust Robinson and J.P. Morgan gave Constellation Pharmaceuticals (NASDAQ: CNST) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Silvan Tuerkcan maintained a Buy rating on Constellation Pharmaceuticals yesterday and set a price target of $55.00. The company’s shares closed last Monday at $32.41.
According to TipRanks.com, Tuerkcan is a 4-star analyst with an average return of 16.6% and a 27.3% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Seattle Genetics.
Currently, the analyst consensus on Constellation Pharmaceuticals is a Strong Buy with an average price target of $47.75.
Based on Constellation Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.15 million. In comparison, last year the company had a GAAP net loss of $19.94 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.